Company: XOMAP
Filing Date: 2025-10-17
Form Type: SC TO-T/A
Source: 0001193125-25-242199
Chunk: 1

Company: XOMA Royalty Corp
Filing Date: 2025-10-17
Form: SC TO-T/A
Chunk 1
---
 to purchase all of the issued and outstanding common shares, with a nominal value of €0.12 per share (“ Shares”), in the capital of LAVA Therapeutics N.V., a public limited liability company ( naamloze vennootschap) organized under the laws of the Netherlands, having its corporate seat ( statutaire zetel) in Utrecht, the Netherlands, registered with the Dutch trade register under number 65335740 (“ LAVA”), for a price per Share of (i) $1.04 (the “ Cash Amount”), and (ii) one non-transferablecontractual contingent value right (“ CVR”) for each Share, which shall represent the right to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement, subject to any applicable tax withholding and without interest (such amount, the “ CVR Amount,” and together with the Cash Amount, the “ Offer Consideration”), all upon the terms and subject to the conditions described in the Amended and Restated Offer to Purchase, dated October 17, 2025 (together with any subsequent amendments or supplements thereto, the “ Offer to Purchase”) filed herewith and in the related Letter of Transmittal, copies of which are attached hereto as exhibits (a)(1)(A) and (a)(1)(B), respectively. The Offer is being made pursuant to the Share Purchase Agreement, dated as of August 3, 2025 (together with any amendments or supplements thereto, the “ Purchase Agreement”), among LAVA and Purchaser, a copy of which is filed as Exhibit (d)(1) hereto and incorporated herein by reference with respect to Items 4 through 11 of this Schedule TO. The purpose of this Amendment is to amend and restate the Schedule TO and the Offer to Purchase, including to disclose that on October 17, 2025, Purchaser and LAVA determined, in accordance with the Purchase Agreement, that the Cash Amount is $1.04 per Share, as determined in accordance with Section 2.01 of the Purchase Agreement. A press release announcing (i) the amendment of the Purchase Agreement and (ii) the determination of the Cash Amount was issued by Purchaser and LAVA on October 17, 2025. Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in